Compare Amphastar Pharmaceuticals Inc (AMPH) vs GE Aerospace (GE) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

GE Aerospace (GE) trades at $359.27, up 0.06% on the day, with strong technical momentum indicated by bullish moving averages and RSI near neutral. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.86 surpassing the $1.60 estimate. Revenue grew to $45.86B in 2025, while net income reached $8.70B, reflecting robust profitability with a net margin of 18.98%. Recent news highlights defense contract wins and commercial engine demand, supporting positive sentiment.

Outlook remains favorable given earnings beats and aerospace sector strength, but high valuation multiples (P/E 44.63) and debt levels pose risks. Analyst consensus is bullish with a $399.43 price target, suggesting ~11% upside. Key risks include execution challenges and macroeconomic pressures on aviation demand.